Pain and depression affect one another, and this bidirectional interaction implies the existence of common or interacting neural pathways. Among the neural circuits relevant to negative affection, the medial prefrontal cortex (mPFC) is known to be involved in both pain and depression. Persistent stress from physical pain and mental distress can evoke maladaptive changes in mPFC circuits to induce depression. Conversely, the unpleasant mood condition alters mPFC circuits to distort the appraisal of aversion and make individuals vulnerable to pain. In this article, recent findings regarding mPFC in chronic pain and/or depression are reviewed, with particular focus on the metabotropic glutamate receptor 5 (mGluR5). Although the involvement of ...
The medial prefrontal cortex (mPFC) modulates a range of behaviors, including responses to noxious s...
Major depressive disorder (MDD) and chronic pain are two complex disorders that often coexist. The u...
Objective: Clinical and preclinical evidence suggest a hyperactive glutamatergic system in clinical ...
Abstract.: Glutamate, by activation of metabotropic receptors (mGluRs), can lead to a reduction of s...
YesGroup I metabotropic glutamate receptor (mGluR) dependent long-term depression (LTD) is a major f...
Pain is an essential protective mechanism meant to prevent tissue damages in organisms. On the other...
The medial prefrontal cortex (mPFC) plays a major role in both sensory and affective aspects of pain...
Despite decades of research on the neurobiology of major depressive disorder (MDD), the mechanisms u...
: group i metabotropic glutamate receptors (mGluRI), including mGluR1 and mGluR5 subtypes, modulate ...
Depression and chronic pain share an intricate, complex relationship, the comorbidity of which is re...
Abstract BACKGROUND: Enhanced supraspinal glutamate levels following nerve injury are associated w...
Depression symptoms are often found in patients suffering from chronic pain, a phenomenon that is ye...
The involvement of the prefrontal cortex in pain processing has been recently addressed. We studied ...
A connection between pain and depression has long been recognized in the clinical setting; however, ...
Chronic pain and major depressive disorder are widespread conditions in the world. Interestingly, th...
The medial prefrontal cortex (mPFC) modulates a range of behaviors, including responses to noxious s...
Major depressive disorder (MDD) and chronic pain are two complex disorders that often coexist. The u...
Objective: Clinical and preclinical evidence suggest a hyperactive glutamatergic system in clinical ...
Abstract.: Glutamate, by activation of metabotropic receptors (mGluRs), can lead to a reduction of s...
YesGroup I metabotropic glutamate receptor (mGluR) dependent long-term depression (LTD) is a major f...
Pain is an essential protective mechanism meant to prevent tissue damages in organisms. On the other...
The medial prefrontal cortex (mPFC) plays a major role in both sensory and affective aspects of pain...
Despite decades of research on the neurobiology of major depressive disorder (MDD), the mechanisms u...
: group i metabotropic glutamate receptors (mGluRI), including mGluR1 and mGluR5 subtypes, modulate ...
Depression and chronic pain share an intricate, complex relationship, the comorbidity of which is re...
Abstract BACKGROUND: Enhanced supraspinal glutamate levels following nerve injury are associated w...
Depression symptoms are often found in patients suffering from chronic pain, a phenomenon that is ye...
The involvement of the prefrontal cortex in pain processing has been recently addressed. We studied ...
A connection between pain and depression has long been recognized in the clinical setting; however, ...
Chronic pain and major depressive disorder are widespread conditions in the world. Interestingly, th...
The medial prefrontal cortex (mPFC) modulates a range of behaviors, including responses to noxious s...
Major depressive disorder (MDD) and chronic pain are two complex disorders that often coexist. The u...
Objective: Clinical and preclinical evidence suggest a hyperactive glutamatergic system in clinical ...